Application of teicoplanin in the preparation of anti-Middle East respiratory syndrome coronavirus drugs

A technology for respiratory syndrome and teicoplanin, applied in the direction of antiviral agents, glycopeptide components, etc., can solve the problems of no antiviral drugs, lack of vaccines and drugs, etc., and achieve the effect of avoiding a long cycle

Active Publication Date: 2018-05-04
SUN YAT SEN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the world still lacks effective vaccines and drugs against MERS-CoV
Currently, there are no ready-made antiviral drugs on the market for MERS-CoV

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of teicoplanin in the preparation of anti-Middle East respiratory syndrome coronavirus drugs
  • Application of teicoplanin in the preparation of anti-Middle East respiratory syndrome coronavirus drugs
  • Application of teicoplanin in the preparation of anti-Middle East respiratory syndrome coronavirus drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1 The inhibitory effect of the compound antibiotic teicoplanin at different concentrations on the envelope protein S of Middle East respiratory syndrome coronavirus (MERS-CoV)

[0038] (1) Encapsulate virus: 4.5 μg pHIV-luciferase, 4.5 μg pCMV-ΔR8.2 and 10 μg MERS-CoV-S plasmids were transfected into 293T cells (10 cm dish). After 48 hours, the virus supernatant was collected and tested. p24.

[0039] (2) Compound screening for MERS-CoV-S: p24-normalized MERS-CoV-S pseudovirus supernatant (containing 8 μg / ml Polybrene) was used to infect 293T cells in a 96-well plate, and at the same time, different concentrations of substitute test were added Lanin compound.

[0040] (3) Change the medium: After 12 hours of infection, change to fresh DMEM medium.

[0041] (4) Detection of luciferase activity: 48 hours after infection, wash each well with PBS once, then add 100 μl lysate, shake for 30 min, and take 10 μl lysate to detect luciferase activity.

[0042] According to the re...

Embodiment 2

[0043] Example 2 The inhibitory effect of the compound antibiotic teicoplanin at different concentrations on the vesicular stomatitis virus envelope VSV-G

[0044] (1) Encapsulate virus: 4.5 μg pHIV-luciferase, 4.5 μg pCMV-ΔR8.2 and 10 μg VSV-G plasmids were transfected into 293T cells (10 cm dish). After 48 hours, the virus supernatant was collected and p24 was measured.

[0045] (2) Compound screening for VSV-G: p24-normalized VSV-G pseudovirus supernatant (containing 8 μg / ml Polybrene) was infected with 293T cells in a 96-well plate, and teicoplanin compounds of different concentrations were added at the same time.

[0046] (3) Change the medium: 12 hours after infection, change to fresh DMEM medium.

[0047] (4) Detection of luciferase activity: 48 hours after infection, wash each well with PBS once, then add 100 ul lysate, shake for 30 minutes, take 10 ul lysate to detect luciferase activity.

[0048] According to the result of Example 2 figure 2 It shows that the antibiotic teico...

Embodiment 3

[0049] Example 3 The inhibitory effect of the compound antibiotic teicoplanin at different concentrations on the envelope protein S of severe acute respiratory syndrome coronavirus (SARS-CoV)

[0050] (1) Encapsulate virus: 6.5 μg pHIV-luciferase, 8 μg pCMV-ΔR8.2 and 20 μg SARS-CoV-S plasmids were transfected into 293T cells (10 cm dish). After 48 hours, the virus supernatant was collected and tested. p24.

[0051] (2) Compound screening for SARS-CoV-S: p24-normalized SARS-CoV-S pseudovirus supernatant (containing 8 μg / ml Polybrene) was infected with 293T cells in 96-well plates, and at the same time added different concentrations of substitute test Lanin compound.

[0052] (3) Change the medium: After 12 hours of infection, change to fresh DMEM medium.

[0053] (4) Detection of luciferase activity: 48 hours after infection, wash each well with PBS once, then add 100 μl of lysate, shake for 30 min, and take 10 μl of lysate to detect luciferase activity.

[0054] According to the resul...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of teicoplanin in preparation of drugs for MERS-CoV (Middle East respiratory syndrome coronavirus). According to the application, teicoplanin compounds have the effect of treating the MERS-CoV in vitro.

Description

Technical field [0001] The present invention relates to new applications of antiviral drugs, and more specifically, to a kind of teicoplanin compound in the preparation of anti-Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV) Application in medicine. Background technique [0002] Middle East Respiratory Syndrome is an acute respiratory disease caused by a new type of coronavirus discovered in 2012. On May 23, 2013, the World Health Organization named this new type of coronavirus infection "Middle East Respiratory Syndrome." The virus first appeared in Saudi Arabia, and then spread to other countries in the Middle East and Europe. The first confirmed case was reported in South Korea in early 2015 and further spread. On May 29, according to a notification from the National Health and Family Planning Commission of my country, the first confirmed case of imported Middle East respiratory syndrome occurred in Huizhou ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/14A61P31/14
Inventor 潘婷周南张辉
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap